ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
25 hedge funds and large institutions have $9.54M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
4% more funds holding
Funds holding: 24 → 25 (+1)
2.78% less ownership
Funds ownership: 34.85% → 32.08% (-2.8%)
36% less capital invested
Capital invested by funds: $14.8M → $9.54M (-$5.29M)
60% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 10
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$768K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$298K |
| 3 |
PFS
Prospera Financial Services
Dallas,
Texas
|
+$278K |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$38.9K |
| 5 |
BBPWM
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
|
+$14.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
BCWM LLC
Overland Park,
Kansas
|
-$2.23M |
| 2 |
Jane Street
New York
|
-$748K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$652K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
-$202K |
| 5 |
Morgan Stanley
New York
|
-$46.3K |
CNCR Hedge Fund Activity: Q4 2021 in Review
25 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q4 2021, worth a combined $9.54M — down 36% from $14.8M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CNCR positions and 5 closed out — a net gain of 1 holder — while 4 added to existing stakes and 10 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $768K. The largest seller was BCWM LLC, cutting an estimated $2.23M.
- 25 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q4 2021, up from 24 in Q3 2021.
- Funds reported $9.54M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q4 2021, down 36% quarter-over-quarter.
- 6 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q4 2021 and 5 closed out, a net change of +1 holder.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q4 2021 was Goldman Sachs, an estimated $768K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q4 2021 was BCWM LLC, an estimated $2.23M sold.
Based on aggregated 13F filings for Q4 2021.